In re Celebrex Antitrust Litig., No. 14-00361 (E.D. Va.), Faruqi & Faruqi representing a pharmaceutical wholesaler and a proposed class of direct purchasers of Pfizer’s blockbuster anti-inflammatory drug, Celebrex, alleging that Pfizer procured a patent by fraud and then filed patent litigation against generic drugmakers to delay their entry into the market with less-expensive generic versions of Celebrex, which had annual sales of over $1 billion during the relevant time. (settled for $94 million)
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 09/13/2014
Office
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771